Allergy denials in California external review
In the California DMHC record, independent physician reviewers decided 58 published external-review cases involving allergyand overturned the plan’s denial in 10.3%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for allergy
| Category | Decisions | Overturned |
|---|---|---|
| Allergy Testing | 23 | 0% |
| Lab Work | 13 | 0% |
| Allergy Rx | 9 | 66.7% |
| Ongoing OON Tx | 8 | 0% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 42 | 0% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 16 | 37.5% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for prednisolone sodium phosphate oral dissolving tablets (Orapred-ODT). It is critical for this for this patient’s family and caregivers to have immediate access to emergency medications, such as epinephrine autoinjectors in case of allergic reactions that occur outside the presence of medical supervision. In addition, adjunctive medications such as systemic steroids and antihistamines, can also be helpful to alleviate the patient’s symptoms. Although systemic steroids should not be used for initial therapy, there is support for their use as an adjunctive therapy per the American Academy of Allergy, Asthma and Immunology (AAAAI) and American College of Allergy, Asthma and Immunology (ACAAI) practice parameters.
Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for prednisolone sodium phosphate oral dissolving tablets (Orapred-ODT). It is critical for this for this patient’s family and caregivers to have immediate access to emergency medications, such as epinephrine autoinjectors in case of allergic reactions that occur outside the presence of medical supervision. In addition, adjunctive medications such as systemic steroids and antihistamines, can also be helpful to alleviate the patient’s symptoms. Although systemic steroids should not be used for initial therapy, there is support for their use as an adjunctive therapy per the American Academy of Allergy, Asthma and Immunology (AAAAI) and American College of Allergy, Asthma and Immunology (ACAAI) practice parameters.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: Allergen-specific IgG4 testing has not been demonstrated in randomized controlled clinical trials to be effective for routine clinical care and is not recommended for the evaluation of IgE-mediated food allergies per expert panel guidelines due to lack of evidence. Also noted in the 2014 Joint Task Force Updated Food Allergy Practice Parameters, “allergen-specific IgG measurement…should not be used for the evaluation of food allergy”. Similarly, allergen-specific IgG testing is not included in recommendations for diagnosis of non-IgE mediated immunologic adverse reactions to foods.
Nature of Statutory Criteria/Case Summary: Allergen-specific IgG4 testing has not been demonstrated in randomized controlled clinical trials to be effective for routine clinical care and is not recommended for the evaluation of IgE-mediated food allergies per expert panel guidelines due to lack of evidence. Also noted in the 2014 Joint Task Force Updated Food Allergy Practice Parameters, “allergen-specific IgG measurement…should not be used for the evaluation of food allergy”. Similarly, allergen-specific IgG testing is not included in recommendations for diagnosis of non-IgE mediated immunologic adverse reactions to foods.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving allergy, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY